NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $4.55 +0.04 (+0.89%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.39▼$4.5650-Day Range$3.12▼$4.5552-Week Range$1.69▼$4.56Volume1.58 million shsAverage Volume886,647 shsMarket Capitalization$858.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arbutus Biopharma alerts: Email Address Arbutus Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.4% Upside$5.25 Price TargetShort InterestHealthy3.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 starsMedical Sector767th out of 910 stocksPharmaceutical Preparations Industry358th out of 426 stocks 2.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.52% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 2.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 2.4 News and Social Media Coverage News SentimentArbutus Biopharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest16 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 220% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.38) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 7.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Arbutus Biopharma Stock (NASDAQ:ABUS)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABUS Stock News HeadlinesSeptember 6 at 5:57 AM | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Price Target Raised to $7.00September 5 at 9:53 PM | markets.businessinsider.comBuy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical DevelopmentsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 5 at 11:50 AM | msn.comArbutus Biopharma to Present at Major Investor Conferences in New YorkSeptember 3, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesAugust 18, 2024 | ca.finance.yahoo.comABUS Sep 2024 4.000 callAugust 3, 2024 | markets.businessinsider.comPromising Clinical Advances for Arbutus Biopharma’s Imdusiran in Hepatitis B TreatmentAugust 3, 2024 | msn.comArbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 2, 2024 | seekingalpha.comArbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call TranscriptAugust 2, 2024 | markets.businessinsider.comArbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy RatingAugust 2, 2024 | bizjournals.comArbutus slashes workforce by 40%, narrows hepatitis B cure effortsAugust 2, 2024 | msn.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | globenewswire.comArbutus Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from Arbutus Biopharma's earningsAugust 1, 2024 | msn.comArbutus Biopharma Q2 2024 Earnings PreviewJuly 20, 2024 | msn.comArbutus Biopharma to Reveal Q2 Financials and Corporate UpdatesJuly 18, 2024 | globenewswire.comArbutus to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateSee More Headlines Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded1992Price Target and Rating Average Stock Price Target$5.25 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+15.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,850,000.00 Net Margins-766.20% Pretax Margin-766.20% Return on Equity-66.68% Return on Assets-50.27% Debt Debt-to-Equity RatioN/A Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual Sales$18.14 million Price / Sales47.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book7.00Miscellaneous Outstanding Shares188,780,000Free Float181,168,000Market Cap$858.95 million OptionableOptionable Beta1.92 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael J. McElhaugh (Age 49)Co-Founder, Interim President, CEO & Director Comp: $606.62kDr. Michael J. Sofia Ph.D. (Age 66)Chief Scientific Officer Comp: $628.43kMr. David C. Hastings CPA (Age 63)CFO & Chief Accounting Officer Comp: $647.1kMs. Lisa M. CaperelliVice President of Investor RelationsMr. J. Christopher Naftzger BA (Age 57)Esq., J.D., General Counsel, Chief Compliance Officer & Secretary Ms. Shannon Briscoe SPHRVice President of Human ResourcesDr. Karen Sims M.D. (Age 53)Ph.D., Chief Medical Officer Mr. R. Hector Mackay-Dunn B.A. (Age 73)J.D., L.L.B., Q.C., Corporate Secretary More ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVKamadaNASDAQ:KMDARedHill BiopharmaNASDAQ:RDHLF-star TherapeuticsNASDAQ:FSTXBeyondSpringNASDAQ:BYSIView All CompetitorsInstitutional OwnershipSusquehanna Fundamental Investments LLCBought 105,228 shares on 8/15/2024Ownership: 0.110%The Manufacturers Life Insurance Company Bought 4,191 shares on 8/15/2024Ownership: 0.030%Bank of Montreal CanBought 20,548 shares on 8/14/2024Ownership: 0.188%ProShare Advisors LLCSold 5,897 shares on 8/14/2024Ownership: 0.015%Rubric Capital Management LPBought 1,681,090 shares on 8/13/2024Ownership: 0.891%View All Institutional Transactions ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $2.50 at the beginning of 2024. Since then, ABUS stock has increased by 82.0% and is now trading at $4.55. View the best growth stocks for 2024 here. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $1.73 million during the quarter, compared to analyst estimates of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative trailing twelve-month return on equity of 66.68%. What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's top institutional investors include Rubric Capital Management LP (0.89%), Bank of New York Mellon Corp (0.26%), Bank of Montreal Can (0.19%) and Susquehanna Fundamental Investments LLC (0.11%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH) and Inovio Pharmaceuticals (INO). This page (NASDAQ:ABUS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
